Skip to content

Study · Measured the body's own peptide · 2017

3 results

Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases.

Majewski K, Żelechowska P, Brzezińska-Błaszczyk E

Clinical and investigative medicine. Medecine clinique et experimentale19 Feb 2017Cited by 12 (Europe PMC)

PMID28218580 (opens in a new tab)DOI10.25011/cim.v40i1.28052 (opens in a new tab)PepBankPUB-28218580
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    Serum levels of the body's own LL‑37 were higher in patients with pulmonary tuberculosis than in patients with Gram-positive pneumonia.

    In plain wordsPeople with tuberculosis had higher natural LL‑37 levels in blood than people with Gram-positive pneumonia.

    Peptide
    LL-37
    Outcome
    IncreaseSerum LL-37 in tuberculosis versus Gram-positive pneumonia
    Study

    n = 60

    Comparator
    Patients with Gram-positive bacteria-induced pneumonia
    Outcome group
    Immune response · Respiratory

    Measurements

    Mean serum LL-37
    13.94 ng/mL
    tuberculosis
    Mean serum LL-37
    7.87 ng/mL
    Gram-positive pneumonia

    Source sentences

    Summary
    The mean (± SEM) LL-37 concentration in patients with TB (13.94±5.13 ng/mL) was significantly higher than that in patients with Gram-positive bacteria-induced pneumonia (7.87±4.58 ng/mL, P=0.00077), in patients with Gram-negative bacteria-induced pneumonia (10.27±3.60 ng/mL, P=0.00730), and in contr…
    2 context sentences
    Summary · context
    Thirty TB patients, 30 patients with pneumonia caused by Gram-positive bacteria, 30 patients with pneumonia caused by Gram-negative bacteria, and 30 healthy control subjects were enrolled in the study.
    Summary · context
    Serum LL-37 concentration was measured using an enzyme-linked immunosorbent assay (ELISA).

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    Serum levels of the body's own LL‑37 were higher in patients with pulmonary tuberculosis than in patients with Gram-negative pneumonia.

    In plain wordsPeople with tuberculosis had higher natural LL‑37 levels in blood than people with Gram-negative pneumonia.

    Peptide
    LL-37
    Outcome
    IncreaseSerum LL-37 in tuberculosis versus Gram-negative pneumonia
    Study

    n = 60

    Comparator
    Patients with Gram-negative bacteria-induced pneumonia
    Outcome group
    Immune response · Respiratory

    Measurements

    Mean serum LL-37
    13.94 ng/mL
    tuberculosis
    Mean serum LL-37
    10.27 ng/mL
    Gram-negative pneumonia

    Source sentences

    Summary
    The mean (± SEM) LL-37 concentration in patients with TB (13.94±5.13 ng/mL) was significantly higher than that in patients with Gram-positive bacteria-induced pneumonia (7.87±4.58 ng/mL, P=0.00077), in patients with Gram-negative bacteria-induced pneumonia (10.27±3.60 ng/mL, P=0.00730), and in contr…
    2 context sentences
    Summary · context
    Thirty TB patients, 30 patients with pneumonia caused by Gram-positive bacteria, 30 patients with pneumonia caused by Gram-negative bacteria, and 30 healthy control subjects were enrolled in the study.
    Summary · context
    Serum LL-37 concentration was measured using an enzyme-linked immunosorbent assay (ELISA).

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    Serum levels of the body's own LL‑37 were higher in patients with pulmonary tuberculosis than in healthy control subjects.

    In plain wordsPeople with tuberculosis had higher natural LL‑37 levels in blood than healthy people.

    Peptide
    LL-37
    Outcome
    IncreaseSerum LL-37 in tuberculosis versus healthy controls
    Study

    n = 60

    Comparator
    Healthy control subjects
    Outcome group
    Immune response · Respiratory

    Measurements

    Mean serum LL-37
    13.94 ng/mL
    tuberculosis
    Mean serum LL-37
    1.75 ng/mL
    healthy controls

    Source sentences

    Summary
    The mean (± SEM) LL-37 concentration in patients with TB (13.94±5.13 ng/mL) was significantly higher than that in patients with Gram-positive bacteria-induced pneumonia (7.87±4.58 ng/mL, P=0.00077), in patients with Gram-negative bacteria-induced pneumonia (10.27±3.60 ng/mL, P=0.00730), and in contr…
    2 context sentences
    Summary · context
    Thirty TB patients, 30 patients with pneumonia caused by Gram-positive bacteria, 30 patients with pneumonia caused by Gram-negative bacteria, and 30 healthy control subjects were enrolled in the study.
    Summary · context
    Serum LL-37 concentration was measured using an enzyme-linked immunosorbent assay (ELISA).

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:57 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.